Evidence map›Paper›PMID 34897561›Full record

ArticleWorld journal of microbiology & biotechnology2021

Design, expression and functional assessment of novel engineered serratiopeptidase analogs with enhanced protease activity and thermal stability.

Maryam Rouhani, Vahideh Valizadeh, Atousa Aghai, Sogol Pourasghar, Sara Molasalehi, Reza Ahangari Cohan, Dariush Norouzian

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of microbiology & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maryam RouhaniDepartment of Tissue Engineering and Applied Cell Science, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Vahideh Valizadeh *Nano-Biotechnology Department, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran. v_valizadeh@pasteur.ac.ir.ORCID http://orcid.org/0000-0002-0806-3626
Atousa AghaiNano-Biotechnology Department, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran.
Sogol PourasgharNano-Biotechnology Department, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran.
Sara MolasalehiDepartment of Tissue Engineering and Applied Cell Science, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Reza Ahangari CohanNano-Biotechnology Department, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran.
Dariush Norouzian *Nano-Biotechnology Department, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran. dnsa@pasteur.ac.ir.
Pasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serratiopeptidase is a bacterial protease that has been used medicinally in variety of applications. Though, some drawbacks like sensitivity to environmental conditions and low penetration into cells limited its usage as a potent pharmaceutical agent. This study aimed to produce four novel truncated serratiopeptidase analogs with different lengths and possessing one disulfide bridge, in order to enhance protease activity and thermal stability of this enzyme. Mutagenesis and truncation were performed using specific primers by conventional and overlap PCR. The recombinant proteins were expressed in E. coli cells then purified and their protease activity and stability were checked at different pH and temperatures in comparison to the native form of the enzyme, Serra473. Enzyme activity assay showed that T306 [12-302 ss] was not further active which could be due to the large truncation. However, T344 [8-339 ss], T380 [8-339 ss] and T380 [12-302 ss] proteins showed higher proteolytic activity comparing to Serra473. These analogs were active at temperatures of 25-90 °C and pH 6-9.5. Interestingly, remaining enzyme activity of T344 [8-339 ss], T380 [8-339 ss] and T380 [12-302 ss] forms at 90 °C calculated as 87, 83 and 86 percent, respectively, comparing to the activity at room temperature. However, residual activity at the same conditions was 50% for the full length enzyme. Formation of disulfide bond in engineered serratiopeptidases could be the main reason for higher thermal stability compared to Serra473. Thermostability of T344 [8-339 ss], as the most thermostable designed serratiopeptidase, was additionally confirmed using differential scanning calorimetry.

Indexed as

Enzyme StabilityBacterial ProteinsEscherichia coliGenetic EngineeringHydrogen-Ion ConcentrationIndustrial MicrobiologyMutagenesis, Site-DirectedPeptide HydrolasesProteolysisRecombinant ProteinsTemperatureBacterial ProteinsPeptide HydrolasesRecombinant ProteinsserratiopeptidaseEnzyme engineeringMetalloproteaseSerratiopeptidaseSite directed mutagenesisThermal stability

Identifiers

PMID34897561
OpenAlexW4200137895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.